Abstract
MicroRNAs (miRNAs) are a new class of negative regulators that repress gene expression by pairing with their target messenger RNAs (mRNAs). There are hundreds of miRNAs coded in the human genome and thousands of target mRNAs participating in a wide variety of physiological processes such as development and cell identity. It is therefore not surprising that several recent reports involved deregulated miRNAs in the complex mechanism of human carcinogenesis, and proposed them as new key regulators to correct the unbalanced expression of oncogenes and tumour suppressor genes exhibited in cancer cells. This review summarises most of the recent patents related to the use of miRNA signatures in cancer diagnosis and prognosis, the detection and profiling of miRNAs from tumour samples and the identification of oncogenes and tumour suppressor genes targeted by miRNAs, as well as new cancer therapies based on miRNA modulators.
Keywords: RNA silencing, RNA interference, gene therapy, microRNA, miRNA, miRNA target, miRNA inhibitor, miRNA mimic, cancer, cancer therapy, cancer diagnosis, patent, Caenorhabditis elegans, Exportin-5, TRBP, RISC, cisplatin, doxorubicin, RISCs, PCR, real-time PCR, FRET, chronic lymphocytic leukaemia, mass spectrometry, ATRA, HSP90, human carcinogenesis
Recent Patents on Anti-Cancer Drug Discovery
Title: Silencing Human Cancer: Identification and Uses of MicroRNAs
Volume: 6 Issue: 1
Author(s): Francisco E. Nicolas, Sara Lopez-Gomollon, Alfonso F. Lopez-Martinez and Tamas Dalmay
Affiliation:
Keywords: RNA silencing, RNA interference, gene therapy, microRNA, miRNA, miRNA target, miRNA inhibitor, miRNA mimic, cancer, cancer therapy, cancer diagnosis, patent, Caenorhabditis elegans, Exportin-5, TRBP, RISC, cisplatin, doxorubicin, RISCs, PCR, real-time PCR, FRET, chronic lymphocytic leukaemia, mass spectrometry, ATRA, HSP90, human carcinogenesis
Abstract: MicroRNAs (miRNAs) are a new class of negative regulators that repress gene expression by pairing with their target messenger RNAs (mRNAs). There are hundreds of miRNAs coded in the human genome and thousands of target mRNAs participating in a wide variety of physiological processes such as development and cell identity. It is therefore not surprising that several recent reports involved deregulated miRNAs in the complex mechanism of human carcinogenesis, and proposed them as new key regulators to correct the unbalanced expression of oncogenes and tumour suppressor genes exhibited in cancer cells. This review summarises most of the recent patents related to the use of miRNA signatures in cancer diagnosis and prognosis, the detection and profiling of miRNAs from tumour samples and the identification of oncogenes and tumour suppressor genes targeted by miRNAs, as well as new cancer therapies based on miRNA modulators.
Export Options
About this article
Cite this article as:
E. Nicolas Francisco, Lopez-Gomollon Sara, F. Lopez-Martinez Alfonso and Dalmay Tamas, Silencing Human Cancer: Identification and Uses of MicroRNAs, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (1) . https://dx.doi.org/10.2174/157489211793980033
DOI https://dx.doi.org/10.2174/157489211793980033 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cross Bridging Proteins in Nature and their Utilization in Bio- and Nanotechnology
Current Protein & Peptide Science The Dynamics of the Hypothalamic-Pituitary-Ovarian Axis, ReproductivePerformance and Sexuality Following Bariatric Surgery
Current Women`s Health Reviews New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry The Relevance of IgE in the Pathogenesis of Allergy: The Effect of an Anti-IgE Drug in Asthma and Other Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Clinical Considerations in Developing Dendritic Cell Vaccine Based Immunotherapy Protocols in Cancer
Current Molecular Medicine Characterization of Breast Lesions by Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS)
Current Medical Imaging Chemotherapy for Prostate Cancer
Current Pharmaceutical Design Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Standardization of Epitopes for Human Chorionic Gonadotropin (hCG) Immunoassays
Current Medicinal Chemistry The Janus Face of Cathelicidin in Tumorigenesis
Current Medicinal Chemistry Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews Quantization of Angiogenesis and Image Analysis
Current Angiogenesis (Discontinued)